Diabetes peroxisome proliferator-activated

Peroxisome Proliferator-Activated Receptors (PPARs) Diabetes Mellitus... 

Peroxisome Proliferator activated receptor (PPAR-GAMMA-2) Insulin Variation of insulin efficacy in the treatment of diabetes (93) Susceptibility to type II diabetes (93)... 

Auboeuf D, Rieusset J, Fajas L, Vallier P, Frering V, Riou JP, et al. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans no alteration in adipose tissue of obese and NIDDM patients. Diabetes 1997 46 1319-1327. 

Schupp, M., Clemenz, M., Gineste, R., Witt, H., Janke, J., Helleboid, S., Hennuer, N., Ruiz, P., Unger, T., Staels, B., and Kintscher, U. (2005). Molecular characterization of new selective peroxisome proliferator-activated receptor y modulators with angiotensin receptor blocking activity. Diabetes 54, 3442-3452. 

HP-jS-CD were added. All compounds were resolved in 20 min (see Figure 5). The data indicated that the validated method offered equivalent and complementary information, in terms of selectivity, sensitivity, accuracy, linearity, and precision, to that of an established gradient LC method employed for similar purposes. Ragaglitazar is a dual peroxisome proliferator-activated receptor ot and y agonist intended to restore insulin sensitivity and correct diabetic dyslipidemia. A chiral CZE method combining two CDs, sulfobutylether-jS-CD and dimethyl-/i-CD, lent itself to the analysis of ragaglitazar, its distomer (the (+)... 

Rangwala SM, Lazar MA. Peroxisome proliferator-activated receptor in diabetes and metabohsm. Trends Pharmacol Sci 2004 25 331-6. 

The farnesoid X receptor is a member of the class of nuclear hormone receptors, which have key roles in development and homeostasis, as well as in many diseases like obesity, diabetes and cancer. The farnesoid X receptor shows structural similarity to the estrogen receptor (ER ), which mediates a broad spectrum of physiological functions such as regulation of reproduction, modulation of bone density, cholesterol transport and breast cancer. The farnesoid X receptor also shows similarity with the peroxisome proliferation-activated receptor y (PPARy), which is involved in fat metabolism, inflammatory and immune responses. The estrogen receptor (ER ), the peroxisome proliferation-activated receptor y (PPARy) and the farnesoid X receptor (FXR) can be clustered in a... 

Several fluorine-containing drugs are currently in development for the treatment of diabetes. These are peroxisome proliferator-activated nuclear receptor (PPAR) agonists, aldose reductase, and dipeptidylpeptidase IV (DPP-IV) inhibitors. 

Camp HS, Li O, Wise SC, Hong YH, Frankowski CL, Shen X, Vanbogelen R, Leff T. Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone. Diabetes 2000 49(4) 539 17. 

Kroetz DL, Yook P, Costet P, Bianchi P, Pineau T. Peroxisome proliferator-activated receptor alpha controls the hepatic CYP4A induction adaptive response to starvation and diabetes. J Biol Chem 1998 273 31581-31589. 

Sidhu JS, Cowan D, Kaski JC, The effects of Rosiglitazone, a peroxisome proliferator activated receptor gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol 2003 42 1757-1763. 

PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR)y AGONISTS FOR DIABETES... 

PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR AGONISTS FOR DIABETES 183... 

Murakami, K., Tobe, K., Ide, T., Mochizuki, T., Ohashi, M., Akanuma, Y., Yazaki, Y., and Kadowaki, T. (1998). A novel insulin sensitizer acts as a coligand for peroxisome proliferator-Activated Receptor-Alpha (PPAR-alpha) and PPAR-Gamma Effect of PPAR-Alpha Activation on Abnormal Lipid Metabolism in Liver of Zucker Fatty Rats. Diabetes AT, 1841-1847. 

Auboeuf, D., Rieusset, J., Fajas, L., Vallier, P., Frering, V., Riou, J. P., Staels, B., Auw-erx, J., Laville, M., and Vidal, H. (1997). Tissue Distribution and Quantification of the Expression of mRNAS of Peroxisome Proliferator-Activated Receptors and Liver X Receptor a in humans. Diabetes 46, 1319-1327. 

Kruszynska, Y. T., Mukheijee, R.,Jow, L., Dana, S., Paterniti,J. R., and 01efsky,J. M. (1998). Skeletal Muscle Peroxisome Proliferator-Activated Receptor-y Expression in Obesity and Non-Insulin-Dependent Diabetes Mellitus. J. Clin. Invest. 101, 543-548. 

Yen, C.-J., Beamer, B. A., Negri, C., Silver, K., Brown, K. A., Yarnell, D. P., Burns, D. K., Roth, J., and Shuldiner, A. R. (1997). Molecular Scanning of the Human Peroxisome Proliferator Activated Receptor y Gene in Diabetic Caucasians Identification of a Prol2Ala PPARy2 Missense Mutation. Biochem. Biophys. Res. Commun. 241, 270-274. 

Ringel, J., Engeli, S., Distler, A., and Sharma, A. M. (1999). Prol2Ala Missense Mutation of the Peroxisome Proliferator Activated Receptor Gamma and Diabetes Mellitus. Biochem. Biophys. Res. Commun. 254, 450-453. 

Buckingham, R. E., Al-Barazanji, K. A., Toseland, C. 1). N. el al. (1998). Peroxisome Proliferator-Activated Receptor-y Agonist, Rosiglitazone, Protects Against Nephropathy and Pancreatic Islet Abnormalities in Zucker Fatty Rrts. Diabetes 47, 1326-1334. 

---